Department of Psychiatry, University of Muenster, Muenster, Germany.
Am J Med Genet B Neuropsychiatr Genet. 2010 Jan 5;153B(1):286-90. doi: 10.1002/ajmg.b.30949.
There is strong evidence for a genetic contribution to the pathogenesis of depression, with the functional catechol-O-methyltransferase (COMT) val158met polymorphism having been suggested as a potential susceptibility factor. In the present study, the effect of COMT val158met on response to electroconvulsive therapy (ECT) was analyzed in a sample of 104 Caucasian patients (f = 71, m = 33) with pharmacologically treatment-resistant Major Depression. The higher active COMT 158val allele was found to be associated with (1) higher pre-ECT severity of depression and (2) better treatment response to ECT particularly regarding the core symptoms of depression as well as sleep-related symptoms. These findings were restricted to the female subgroup of patients. In summary, the present study supports a potentially gender-specific significant impact of COMT gene variation on electroconvulsive therapy response, with COMT 158val risk allele carriers suffering from more severe, pharmacologically less efficiently treatable depression and thus possibly deriving greater benefit from ECT in the first place.
有强有力的证据表明,抑郁症的发病机制与遗传有关,儿茶酚-O-甲基转移酶(COMT)的 val158met 多态性被认为是一个潜在的易感因素。在本研究中,分析了 COMT val158met 对 104 例高加索裔(f = 71,m = 33)药物难治性重度抑郁症患者电惊厥治疗(ECT)反应的影响。发现高活性的 COMT 158val 等位基因与以下方面有关:(1)ECT 前抑郁症严重程度较高,(2)对 ECT 的治疗反应较好,特别是对抑郁症的核心症状和与睡眠有关的症状。这些发现仅限于女性患者亚组。总之,本研究支持 COMT 基因变异对电惊厥治疗反应的潜在性别特异性显著影响,COMT 158val 风险等位基因携带者患有更严重、药物治疗效果较差的抑郁症,因此可能首先从 ECT 中获益更多。